- Report
- May 2024
- 183 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- July 2022
- 120 Pages
Global
From €4112EUR$4,325USD£3,454GBP
- Book
- July 2023
- 304 Pages
The Point of Care Biosensors market is a subset of the biotechnology industry that specializes in the development and commercialization of devices capable of conducting diagnostic tests in close proximity to patient care locations, such as clinics, hospitals, and in some cases, patients' homes. These biosensors are designed for rapid analysis of various biological markers indicative of diseases or medical conditions. The technology typically integrates a biological component, such as enzymes or antibodies, with an electronic system to produce quantitative or semi-quantitative results. The increasing demand for quick and easy-to-use diagnostic tools, along with advancements in nanotechnology, microfluidics, and bioelectronics, has spurred innovation in this market.
The sector is driven by the need for immediate results, which enables timely clinical decision-making, and the miniaturization of diagnostic equipment. Point of Care Biosensors cater to a diverse range of applications, including blood glucose monitoring, infectious disease testing, cardiac markers evaluation, and drug abuse testing. They are characterized by their user-friendly designs, portability, and in some cases, connectivity options that allow for remote patient monitoring and data sharing with healthcare providers.
Key players in the Point of Care Biosensors market include Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, and Danaher Corporation. These companies are engaged in the research, development, and commercialization of innovative biosensor technologies to meet the diagnostic needs of healthcare professionals and patients alike. Other notable participants in the market comprise BioMérieux, Becton Dickinson Show Less Read more